Anju Software Anju Software Continues to Build the Next Generation Life Science Software and Data Platform Through Acquisition of MDCPartners
About Anju Software
Anju Software is a leading provider of comprehensive software solutions to the life sciences industry. The Company provides an integrated platform spanning clinical, medical affairs and after-market functions for pharmaceutical, biotech and medical device companies and clinical research organizations. Anju was founded by a group of operating professionals with deep software domain expertise and intent on building the next generation platform for the life sciences sector. Over the past two years, Anju has acquired five companies:
Online Business Applications – Market leader in medical information solutions and pharmacovigilance
OpenQ – Solutions for key opinion leader (KOL) engagement and management
ClinPlus – Provider of comprehensive electronic data capture (EDC), clinical trials management software (CTMS), electronic trial master file (eTMF) solutions
Sylogent – Clinical data capture and publishing planning solutions
MDCPartners – Business intelligence solutions
Anju Software is a portfolio company of Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners, a global private equity firm with over $57 billion in capital under management.
MDCPartners provides business intelligence data solutions for clinical trial optimization, medical expert identification and competitive intelligence. With deep expertise in the fields of data mining, semantic processing and engineering, MDC provides its clients with event-based tools to monitor and analyze an ever-expanding world of public and private data. With their proprietary data solutions, users can transform millions of scattered data points into a robust snapshot of a therapeutic area. MDC combines its expertise in drug development processes with its unique IT architecture to provide cost effective information solutions to the pharmaceutical and biotech industry. MDCPartners offers a product suite that includes: ta-Scan, a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data and expert profiles; and normScan: web-based standards tracking tool tailored to clients’ product range. For more information, please visit www.mdcpartners.be.
About Providence Equity
Providence is a premier global private equity firm with more than $57 billion in capital under management. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm's inception in 1989, Providence has invested in more than 160 companies and is a leading equity investment firm focused on the media, communications, education and information industries. Providence is headquartered in Providence, RI, and also has offices in New York and London. For more information, please visit www.provequity.com.
NEW YORK--(BUSINESS WIRE)--Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Antwerp-based MDCPartners, a company that specializes in business intelligence data solutions for clinical trial optimization, medical expert identification and competitive intelligence.
“MDCPartners will enable Anju to provide additional value added solutions to pharmaceutical, biotech and medical device companies. This acquisition strengthens Anju’s current product portfolio and can now provide up-to-date comprehensive data for Medical Expert Engagement and Clinical Trial Optimization. MDC, which is based in Belgium, also provides us with operations in Europe to better service our global customers,” said Mr. Kurien Jacob, CEO of Anju Software.
“Anju’s approach and philosophy provides us with financial strength and scale as well as additional resources to support our growth strategy and guide our clients over the long-term,” added Mireille De Cre, co-founder and CEO of MDCPartners.
“With the acquisition of MDCPartners, Anju continues its accelerated growth within the Medical Affairs and clinical trial sectors. Anju is now recognized as an emerging leader in the life science software industry, providing end-to-end software solutions that help customers manage mission critical pharma processes and turn data into actionable insights. We continue to be impressed with what the Anju management team, led by CEO Kurien Jacob, has been able to achieve in a short period of time,” said Gopi Vaddi, Managing Director of Providence Strategic Growth.
Snell and Wilmer acted as legal counsel to Anju and Madison Park Group acted as financial advisors to Anju on the transaction.